scholarly article | Q13442814 |
P50 | author | Michal Vrablík | Q17311886 |
Richard Češka | Q47504165 | ||
P2093 | author name string | Dana Dlouhá | |
Jaroslav A Hubáček | |||
Vera Adámková | |||
Ondřej Viklický | |||
Petra Hrubá | |||
Lukáš Zlatohlavek | |||
P2860 | cites work | SLCO1B1 variants and statin-induced myopathy--a genomewide study | Q29619028 |
SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group | Q34047278 | ||
Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants | Q34163351 | ||
Cerivastatin, genetic variants, and the risk of rhabdomyolysis | Q34792178 | ||
Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study | Q35964012 | ||
The SLCO1B1*5 genetic variant is associated with statin-induced side effects | Q36158024 | ||
SLCO1B1 Polymorphisms and Statin-Induced Myopathy | Q37410969 | ||
Statin myotoxicity: a review of genetic susceptibility factors | Q38157284 | ||
Drug metabolising enzyme polymorphisms in Middle- and Eastern-European Slavic populations | Q38170960 | ||
Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics | Q38173637 | ||
Statin-associated myopathy: from genetic predisposition to clinical management. | Q38271891 | ||
Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. | Q38454155 | ||
Global analysis of genetic variation in SLCO1B1. | Q39340828 | ||
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. | Q42757090 | ||
Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. | Q43062928 | ||
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study | Q46130568 | ||
[The Atractiv project: improvement of cardiovascular preventive in primary care in the Czech Republic] | Q51433897 | ||
Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. | Q54281855 | ||
SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. | Q54559255 | ||
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin | Q57825140 | ||
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid | Q57825144 | ||
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin | Q57825149 | ||
Impact of variants within seven candidate genes on statin treatment efficacy | Q85272567 | ||
P304 | page(s) | 1454-1459 | |
P577 | publication date | 2015-05-20 | |
P1433 | published in | Medical Science Monitor | Q15756323 |
P1476 | title | SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population | |
P478 | volume | 21 |
Q36256049 | Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies |
Q57151967 | Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis |
Q47676842 | Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study |
Q35763066 | Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations |
Q92156926 | Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components |
Search more.